Insmed (NASDAQ:INSM - Free Report) had its target price boosted by UBS Group from $105.00 to $110.00 in a research report released on Thursday, MarketBeat Ratings reports. UBS Group currently has a buy rating on the biopharmaceutical company's stock.
A number of other research analysts have also weighed in on the company. JPMorgan Chase & Co. upped their price objective on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Royal Bank of Canada began coverage on shares of Insmed in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $100.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $90.00 target price on shares of Insmed in a research report on Friday, February 21st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, Wells Fargo & Company upped their price target on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $93.33.
Read Our Latest Research Report on Insmed
Insmed Stock Performance
Shares of INSM stock traded down $1.82 during mid-day trading on Thursday, hitting $73.07. The stock had a trading volume of 1,994,176 shares, compared to its average volume of 1,981,408. Insmed has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company's 50-day simple moving average is $75.66 and its 200-day simple moving average is $73.79. The firm has a market cap of $13.23 billion, a PE ratio of -13.07 and a beta of 1.28.
Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Sell-side analysts anticipate that Insmed will post -4.56 earnings per share for the current year.
Insider Activity at Insmed
In other news, CFO Sara Bonstein sold 3,470 shares of the business's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00. Following the completion of the sale, the chief financial officer now directly owns 114,736 shares of the company's stock, valued at $7,538,155.20. The trade was a 2.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO William Lewis sold 2,978 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.36, for a total value of $188,686.08. Following the completion of the transaction, the chief executive officer now directly owns 392,589 shares in the company, valued at $24,874,439.04. This trade represents a 0.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 550,957 shares of company stock valued at $42,859,028. 4.60% of the stock is owned by insiders.
Institutional Investors Weigh In On Insmed
Institutional investors have recently added to or reduced their stakes in the company. Elequin Capital LP acquired a new stake in Insmed during the 4th quarter worth approximately $28,000. Steward Partners Investment Advisory LLC increased its position in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 163 shares in the last quarter. V Square Quantitative Management LLC raised its stake in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 248 shares during the period. Spire Wealth Management acquired a new position in shares of Insmed during the 4th quarter valued at $47,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 411 shares in the last quarter.
About Insmed
(
Get Free Report)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Read More
Before you consider Insmed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.
While Insmed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
